tiprankstipranks
Trending News
More News >
Immucell Corp. (ICCC)
NASDAQ:ICCC
Advertisement

Immucell (ICCC) AI Stock Analysis

Compare
77 Followers

Top Page

ICCC

Immucell

(NASDAQ:ICCC)

Rating:59Neutral
Price Target:
$6.50
▲(8.33%Upside)
Immucell's stock score reflects solid financial growth and improved earnings performance, but it is weighed down by bearish technical indicators and valuation concerns. The earnings call provided a positive outlook, though challenges with FDA approval and backlog management persist. The financial performance and earnings call were the most significant factors in the evaluation.

Immucell (ICCC) vs. SPDR S&P 500 ETF (SPY)

Immucell Business Overview & Revenue Model

Company DescriptionImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
How the Company Makes MoneyImmucell generates revenue primarily through the sale of its animal health products, which are marketed to dairy and beef cattle producers. The company's key revenue stream is its First Defense product line, which is designed to prevent scours in newborn calves by providing immediate passive immunity. Immucell also invests in research and development to expand its product offerings and improve existing ones, which contributes to growth in its market share. Additionally, the company may engage in strategic partnerships and collaborations to enhance distribution and increase market penetration, thereby boosting its sales and revenue.

Immucell Earnings Call Summary

Earnings Call Date:May 14, 2025
(Q1-2025)
|
% Change Since: 22.20%|
Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.
Q1-2025 Updates
Positive Updates
Record-Breaking Sales Growth
Product sales during the first quarter of 2025 increased by 11% or $810,000 over the first quarter of 2024, reaching a record $8.1 million. This surpassed the previous record set in the fourth quarter of 2024.
Gross Margin Improvement
The gross margin increased to 42% in Q1 2025, up from 37% in Q4 2024, indicating operational improvements and higher production efficiency.
Significant Adjusted EBITDA Growth
Adjusted EBITDA improved significantly to $2.3 million in Q1 2025, compared to $458,000 in Q1 2024.
Successful Production Capacity Expansion
ImmuCell's production capacity increased to over $30 million annually, supporting future growth and reducing backlog from $4.4 million to $3.4 million.
First Defense Product Line Expansion
Introduction of new product formats for First Defense, expanding its use and market appeal.
No Recent Contamination Events
No contamination events reported for over a year, indicating improved production processes.
Negative Updates
Continued Challenges with Re-Tain FDA Approval
Delays in FDA licensing for Re-Tain due to inspection issues at a contract manufacturer, affecting the timeline for full commercial sales.
Backlog Management
Although reduced, the backlog still stands at $3.4 million, indicating ongoing demand and supply chain challenges.
Dependency on High Seasonal Sales
Q1 sales benefited from seasonal high demand, suggesting potential variability in future quarters.
Company Guidance
During the recent ImmuCell Corporation conference call, the company provided several key financial metrics and insights for the first quarter of fiscal year 2025. ImmuCell reported a record quarterly product sales revenue of $8.1 million, marking an 11% increase from the same period in 2024. The company also achieved a gross margin of 42% for the quarter, up from 37% in the fourth quarter of 2024, although they aim to reach at least 45%. Adjusted EBITDA showed significant improvement, with $2.3 million for the first quarter, compared to just $458,000 in the first quarter of 2024. The company's cash balance increased to $4.6 million as of March 31, 2025. ImmuCell reduced its order backlog from $4.4 million at the end of 2024 to $4 million by the end of the first quarter of 2025, with further reductions to $3.4 million by early May 2025. The company completed investments to expand production capacity to over $30 million annually, which contributed to their recent growth and financial recovery.

Immucell Financial Statement Overview

Summary
Immucell shows promising revenue growth and a strong equity foundation. However, it faces challenges in sustaining profitability and positive free cash flow. The improvements in operating cash flow are encouraging, but the company must address its profitability issues to enhance its financial health.
Income Statement
60
Neutral
The company has demonstrated significant revenue growth, especially noted in the TTM period with a substantial increase in total revenue. However, profitability margins such as EBIT and net profit margins have been negative in recent annual reports, indicating ongoing challenges in achieving operational profitability.
Balance Sheet
70
Positive
The balance sheet shows a solid equity position with relatively moderate leverage, as indicated by a reasonable debt-to-equity ratio. The equity ratio is healthy, reflecting the company's ability to finance its operations through shareholder equity rather than excessive debt.
Cash Flow
65
Positive
The company is generating a positive operating cash flow, especially in the TTM period, which indicates improvement in operational cash generation. However, past periods show negative free cash flow, which raises concerns about the company's ability to sustain capital expenditures and finance operations without external funding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue26.49M17.47M18.57M19.24M15.34M
Gross Profit7.94M4.40M7.65M8.66M6.86M
EBITDA1.04M-2.50M349.99K2.72M1.65M
Net Income-2.16M-5.77M-2.49M-78.00K-1.02M
Balance Sheet
Total Assets45.10M43.81M44.86M44.47M40.35M
Cash, Cash Equivalents and Short-Term Investments3.76M978.74K5.79M10.19M7.95M
Total Debt15.10M16.69M12.48M10.27M10.73M
Total Liabilities17.58M18.82M14.48M11.89M12.08M
Stockholders Equity27.52M24.99M30.38M32.58M28.27M
Cash Flow
Free Cash Flow-107.82K-6.57M-5.52M-1.65M-2.76M
Operating Cash Flow357.90K-4.67M-1.54M954.17K1.32M
Investing Cash Flow-461.23K-1.89M-3.96M-1.60M-2.57M
Financing Cash Flow2.88M1.75M1.11M3.88M1.91M

Immucell Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price6.00
Price Trends
50DMA
6.53
Negative
100DMA
5.85
Positive
200DMA
5.21
Positive
Market Momentum
MACD
-0.03
Positive
RSI
38.20
Neutral
STOCH
10.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Neutral. The current price of 6 is below the 20-day moving average (MA) of 6.56, below the 50-day MA of 6.53, and above the 200-day MA of 5.21, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.20 is Neutral, neither overbought nor oversold. The STOCH value of 10.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ICCC.

Immucell Risk Analysis

Immucell disclosed 9 risk factors in its most recent earnings report. Immucell reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Immucell Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$54.22M-1.01%28.29%87.42%
51
Neutral
$7.35B0.50-65.61%2.47%15.28%1.44%
$70.14M-20.33%
50
Neutral
$68.95M-68.14%
42
Neutral
$52.05M-82.81%-92.95%-50.02%
27
Underperform
$55.47M-55.83%59.75%
$52.38M-876.77%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ICCC
Immucell
6.00
2.30
62.16%
MNOV
Medicinova
1.43
0.22
18.18%
ACET
Adicet Bio
0.67
-0.63
-48.46%
HOWL
Werewolf Therapeutics
1.16
-0.76
-39.58%
TELO
Telomir Pharmaceuticals, Inc.
1.76
-1.66
-48.54%
ARTV
Artiva Biotherapeutics, Inc.
2.83
-8.27
-74.50%

Immucell Corporate Events

Executive/Board Changes
ImmuCell Announces CEO Succession Planning Process
Neutral
Jun 25, 2025

On June 25, 2025, ImmuCell Corporation announced the commencement of its CEO succession planning process as current CEO Michael F. Brigham plans to retire by early 2026. The company has begun the search for a new CEO, with the goal of selecting a candidate by the end of the year. Brigham, who has been with ImmuCell since 1989 and served as CEO since 2000, will assist in the transition and continue to serve on the Board of Directors through June 2026. This transition marks a significant moment for ImmuCell as it seeks leadership to continue its growth and innovation in the animal health industry.

Executive/Board ChangesShareholder Meetings
Immucell Elects Directors, Rejects Compensation Proposals
Neutral
Jun 17, 2025

Immucell held its 2025 Annual Meeting of Stockholders on June 12, 2025, via remote communication. During the meeting, all seven director nominees were elected, but the proposals to approve the executive compensation program and amend the 2017 Stock Option and Incentive Plan were not approved. However, the selection of Wipfli LLP as the independent registered public accounting firm for 2025 was ratified.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025